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To assess the efficacy and safety of restrictive versus liberal red blood cell transfusion
thresholds in very low birth weight infants.

Methods
We searched MEDLINE, EMBASE, and Cochrane database without any language restrictions. The last search was conducted in August 15, 2020. All randomized controlled trials
comparing the use of restrictive versus liberal red blood cell transfusion thresholds in very
low birth weight (VLBW) infants were selected. Pooled risk ratio (RR) for dichotomous variable with 95% confidence intervals were assessed by a random-effects model. The primary
outcome was all-cause mortality.

Results
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Overall, this meta-analysis included 6 randomized controlled trials comprising 3,483 participants. Restrictive transfusion does not increase the risk of all-cause mortality (RR, 0.99;
95% CI, 0.84 to 1.17; I2 = 0%; high-quality evidence), and does not increase the composite
outcome of death or neurodevelopmental impairment (RR, 1.01, 95% CI, 0.93–1.09; I2 =
7%; high-quality evidence) or other serious adverse events. Results were similar in subgroup analyses of all-cause mortality by weight of infants, gestational age, male infants, and
transfusion volume.

Conclusions
In very low birth weight infants, a restrictive threshold for red blood cell transfusion was not
associated with increased risk of all-cause mortality, in either short term or long term.
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PLOS ONE | https://doi.org/10.1371/journal.pone.0256810 August 30, 2021

1 / 14

PLOS ONE

Transfusion thresholds in VLBW infants

Introduction
Up to 90% of the preterm infants with body weight at birth of less than 1000 g receive packed
red blood cell (RBC) transfusion at least once during their hospital stay [1,2]. The benefits of
blood transfusion include maintaining high hemoglobin and some additional benefits [3,4].
Maintaining hemoglobin at high levels was considered helpful for improving oxygen delivery
and oxygen consumption [5]. While hemoglobin at low levels would have an adverse impact
on growth [6]. Additionally, some studies suggested that blood transfusions can reduce the
risks of hypoxemia and apnea of prematurity compared with the infants who do not receive
transfusions [7,8]. However, other research showed that RBC transfusion was associated with
increased risk of adverse events and complications, including retinopathy of prematurity [9–
11], bronchopulmonary dysplasia [12,13], necrotizing enterocolitis [14,15]. These complications raise concerns about the safety of this treatment method [16].
Previous randomized controlled trials (RCTs) failed to demonstrate statistically significant
differences in short-term outcomes, such as 30-day or in-hospital mortality in very low birth
weight (VLBW) infants managed with restrictive transfusion criteria compared to those managed according to more liberal criteria, suggesting that the restrictive criteria may reduce the
need for transfusion as well as not increase related side effects [17–19]. However, some cohort
studies which evaluated long-term outcomes of school-age children found that cognitive
impairment and reduced brain volumes may be more common with liberal transfusion thresholds [20,21]. Moreover, it is well known that blood transfusion is an important source of iron.
Iron deficiency [22] and iron overload [12] have been considered as important risk factors for
neurodevelopmental impairment [23]. However, current evidences do not indicate whether
different blood transfusion strategy will affect hemoglobin levels and whether it will affect neurodevelopment. Since restrictive thresholds will theoretically reduce the use of RBC transfusions without increasing the risk of short-term mortality, a 2015 guideline suggest that it is
preferable to adopt a restrictive criteria for VLBW requiring RBC transfusion [24,25]. However, due to the lack of randomized trials at that time, the transfusion criteria are based more
on consensus of opinion of “experts” than on scientific evidence. There is an urgent need to
determine whether a restrictive transfusion strategy is effective in limiting transfusions without
increasing long-term mortality and morbidity in this population.
Thus, this systematic review and meta-analysis evaluated whether restrictive transfusion
was associated with higher rates of death and long-term neurodevelopmental impairment in
very low birth weight infants using data from the longest available follow-up.

Methods
Protocol and guidance
The methods and reporting of the systematic review and meta-analysis followed Preferred
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [26]. The
protocol of this study was registered in PROSPERO database (CRD42020207874).

Data sources
One of the authors (LJ)searched Ovid MEDLINE, Ovid EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) without any language restrictions. The last search was
conducted in August 15, 2020. We also performed a recursive search of the bibliographies of
these selected articles as well as published systematic reviews on this topic, to identify any additional studies. We searched trial registries on WHO International Trials Registry Platform for
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ongoing studies or the availability of completed studies with reported results. The details of the
search strategy conducted are presented in S1 Table.

Eligibility criteria
Inclusion Criteria: (1) Population: participants considered as VLBW (birth weight <1500 g) or
extremely low birth weight (ELBW: birth weight <1000 g) infants. (2) Intervention: restrictive
transfusion thresholds used throughout the infants’ hospitalization. (3) Comparison intervention: liberal transfusion thresholds used throughout the infants’ hospitalization. (4) Outcome:
At least one outcome of interest had to be reported. The primary outcome was all-cause mortality and long-term neurodevelopmental impairment follow-up outcome at least 18 months.
All-cause mortality was categorized into short-term and long-term. Short-term mortality was
defined as in-hospital mortality or 30-day mortality. Long-term mortality was defined as follow-up period of more than 12 months. Secondary efficacy outcome was the composite outcome of death or neurodevelopmental impairment with a follow-up of at least 12 months.
Secondary safety outcomes included periventricular leukomalacia, bronchopulmonary dysplasia, necrotizing enterocolitis, intestinal perforation, retinopathy of prematurity stage 3 and
above, sepsis, length of hospital stay, intraventricular hemorrhage grade 3 and above and
hemoglobin levels. (5) Study design: randomized controlled trials.

Study selection
Study selection followed PRISMA guidelines. After deleting duplicates, we excluded publications that were not eligible based on titles and abstracts. Then full-text articles were reviewed
and either excluded or included in the analysis based on the aforementioned criteria.
Two reviewers (HD and YH) independently completed this procedure together. Conflicts
in study selection were resolved by consensus, or determined by a third independent reviewer
(YZ) if necessary.

Data collection process
Two reviewers (PW and XW) independently extracted data associated with the following
items onto a standardized form: (1) study characteristics: primary author, recruitment period,
year of publication, geographical location and centers where study was conducted, and duration of follow-up; (2) patient characteristics: age, sex; (3) treatment characteristics. Disagreements were resolved through discussion between the two reviewers, with arbitration by a
senior review if necessary. Missing information was obtained by contacting the corresponding
authors of the studies.

Risk of bias and quality of evidence
Risk of bias for all RCTs was assessed using the Cochrane Collaboration Risk of Bias tool
across seven domains: random sequence generation; allocation concealment; blinding of study
participants, blinding of outcome assessment, incomplete outcome data, selective reporting
and other potential sources of bias. Each domain was assessed as low, unclear or high risk of
bias [27]. Two reviewers (PW and XW) independently rated the confidence in the estimates of
effect for each outcome to summarize results in an evidence profile by using the Grading of
Recommendations, Assessment, Development, and Evaluation (GRADE) across five domains
including limitation in design, inconsistency, imprecision, indirectness, and publication bias
[28]. Each domain was assessed as no risk, serious risk, or very serious risk. Evidence would be
considered as high-quality if all domains were rated as no risk. Disagreements were resolved

PLOS ONE | https://doi.org/10.1371/journal.pone.0256810 August 30, 2021

3 / 14

PLOS ONE

Transfusion thresholds in VLBW infants

through discussion between the two reviewers, with arbitration by a senior review (YZ) if
necessary.

Data synthesis
We performed statistical analyses using RevMan (5.4.0; The Cochrane Collaboration). We
reported the results obtained after pooling each individual study with random-effects models
to estimate pooled mean difference (MD) for continuous variable and risk ratio (RR) for
dichotomous variable, with 95% confidence intervals (CIs). Heterogeneity was assessed using
with the I2 test, I2 > 50% being considered substantial and needed further investigation [29].
The small study effect (ie, a tendency of smaller studies to give higher risk estimates) was
assessed by using a visual estimate of the funnel plot and the regression tests Egger’s test,
Begg’s test, and Harbord’s test when 10 or more trials were pooled [30]. A two-sided p value of
less than 0.05 was regarded as statistically significant.

Subgroup analysis
We did subgroup analyses for the following variables: (1) whether including only ELBW
infants (Yes or No), (2) gestational age (� 28 weeks or < 28 weeks), (3) male infants (� 50%
or <50%), (4) transfusion volume (� 20 ml/kg or < 20 ml/kg).

Sensitivity analyses
We conducted sensitivity analyses for the primary outcome by (1) excluding trials one at a
time, (2) using fixed-effect models, (3) excluding trials with less than 500 patients.

Trial sequential analysis
Trial sequential analysis (TSA) was used to calculate the required information size in this
meta-analysis by incorporating the information size and the effect size [31]. Using this
method, we can explore whether cumulative data were adequately powered to draw firm conclusion. Data analysis was conducted using TSA Viewer, version 0.9.5.10 Beta (Copenhagen
Trial Unit, Centre for Clinical Intervention Research, Denmark).
We used a family-wise error rate of 5%, a power of 80% (β of 20%), and a D2 suggested by
including trials in the meta-analysis [32,33]. We used an anticipated relative risk reductions
(RRRs) or relative risk increases (RRIs) of 20%, and the pooled event rate was estimated across
the included studies in the TSA.

Results
Study selection and study characteristics
The initial search yielded 1303 articles. Finally, 6 trials were included in the systematic review
and meta-analysis [17–19,34–37]. The PRISMA flow chart showing the publication screening
process and a list of excluded studies with reasons for exclusion are provided in Fig 1.
Table 1 summarizes the study characteristics. The studies were published from 1984 to
2020. Population sizes ranged from 56 to 1,824 patients. Three trials included only extremely
low birth weight infants [18,35–37]. The birth weight range that was used for inclusion are
listed in Table 1. Definitions of restrictive and liberal transfusion thresholds of each trial are
listed in S2 Table.
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Fig 1. PRISMA flow chart of the studies recruited in this meta-analysis.
https://doi.org/10.1371/journal.pone.0256810.g001

Risk of bias and quality of evidence
Risk of bias is shown in S1 and S2 Figs. None study fulfilled all of the methodological criteria.
All studies performed randomization and allocation concealment. Caregivers were not blinded
in any of the studies, which some of the studies attribute to the ethical issues. Outcome assessors were blinded to the treatment group. Key findings of GRADE assessment of certainty for
the main outcomes are shown in Table 2. The quality of evidence of the primary outcome was
ranked as high.

All-cause mortality
The pooled RR showed no significant difference in overall all-cause mortality between restrictive and liberal transfusion (RR 0.99, 95% CI [0.84, 1.17]; Fig 2A). Three studies with a total of
3,186 patients investigated long-term mortality between restrictive and liberal transfusion
thresholds. Overall, death occurred in 227 of 1,604 infants (14.2%) assigned to the restrictive
transfusion and in 229 of 1,582 infants (14.5%) assigned to the liberal transfusion. Restrictive
transfusion threshold was not associated with increased risk of long-term mortality (RR 0.99,
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Table 1. Characteristics of included trials.
Trial

Setting

No. of
infants

Participants a

Primary outcome

Transfusion
volume

Gestational age in
weeks, mean (SD)
Restrictive Liberal

Kirpalani
2020 [37]

41 NICUs in the
United States

1824

Infants with a birth weight of less
than 1000 g and a postnatal age of
less than 48 hours. No. available
for analysis: restrictive (n = 913),
liberal (n = 911)

The primary outcome was a composite of
death or neurodevelopmental impairment
in infants at 22 to 26 months of age

15 ml/kg

25.9 (1.5)

25.9
(1.5)

Franz 2020
[35]

36 level III/IV
neonatal
intensive care
units in Europe

1013

Infants with birth weights of 400 g
to 999 g and a postnatal age of less
than 72 hours. No. available for
analysis: restrictive (n = 460),
liberal (n = 491)

The primary outcome was death or
disability measured at 24 months of
corrected age

20 ml /kg

26.4 (1.9)

26.1
(2.0)

Chen 2009
[17]

NICU of
Kaohsiung
Medical
University
Hospital

36

Premature infants with birth
weight less than 1500 g. No.
available for analysis: restrictive
(n = 19), liberal (n = 17)

The primary outcome was death before day
30

10 ml/kg

29.1 (3.0)

29.1
(2.7)

Kirpalani
2006 [18],
Whyte 2009
[36]

10 NICUs in
Canada, the
United States,
and Australia.

451

Infants with birth weight <1000g,
and a postnatal age of less than 48
hours. No. available for analysis:
restrictive (n = 223), liberal
(n = 228)

For Whyte 2009, the primary outcome was
a composite of death or
neurodevelopmental impairment in
survivors at 18 months’ corrected age. For
Kirpalani 2006, the primary outcomes were
mortality, ROP, BPD, and Brain injury
before first neonatal discharge home

15 ml/kg

26.0 (2.0)

26.0
(2.0)

103

Infants with birth weight between The primary outcome was mortality to
500 and 1300 g. No. available for
discharge
analysis: restrictive (n = 50), liberal
(n = 53)

15 ml/kg

27.7 (1.7)

27.8
(2.1)

56

Infants with birth weight <1500g. The primary outcome was length of
No. available for analysis:
hospital stay
restrictive (n = 30), liberal (n = 26)

——

29.4 (2.6)

29.8
(1.8)

Bell 2005 [19] University of
Iowa Carver
College of
Medicine
Blank 1984
[34]

NICU of
Lutheran General
Hospital

NICU: A neonatal intensive care unit; SD: Standard deviation.
a

The number of participants available for the primary outcome of this meta-analysis is written.

Note that the primary outcome defined in the original article may differ from the primary outcome in this meta-analysis.
https://doi.org/10.1371/journal.pone.0256810.t001

95% CI [0.83, 1.17]; Fig 2B). Four studies with a total of 2,414 patients investigated short-term
mortality. Death occurred in 178 of 1,205 infants (14.8%) assigned to the restrictive transfusion
and in 171 of 1,209 infants (14.1%) assigned to the liberal transfusion. Restrictive transfusion
threshold was not associated with increased risk of short-term mortality (RR 1.05, 95% CI
[0.86, 1.27]; Fig 2C). The I2 statistic detects no heterogeneity (I2 = 0%). Funnel plot analysis
showed no asymmetry (S3 Fig). Since the cumulative Z-curve crossed the boundary for futility,
we might accept at least a 20% RRR (S4 Fig).
All-cause mortality was robust to sensitivity analyses, as all of the following were similar to
the overall result: by excluding trials at each time, using fixed-effect models, and excluding trials with less than 500 patients (S3 Table). Subgroup analyses did not detect any beneficial effect
within any specific subgroups on the following variables: (1) whether including only ELBW
infants, (2) gestational age, (3) male infants, (4) transfusion volume (Fig 3).

The long-term neurodevelopmental impairment
Two trials with a total of 1739 patients investigated long-term neurodevelopmental
impairment between restrictive and liberal transfusion thresholds. One trial assessed the
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Table 2. Summary of findings and strength of evidence of outcomes.
Outcome
All-cause mortality

No. of patients
(Trials)

RR/MD (95%
CI)

I2

Absolute effect estimates (per 1000)
Intervention Control

Difference

Quality of the
evidence

3325 (5)

0.99 [0.84, 1.17]

0%

140

141

-1 [-23, 24]

High

Long-term mortality

3186 (3)

0.99 [0.83, 1.17]

0%

144

145

-1 [-25, 25]

Moderate §

Short-term mortality

2414 (4)

1.05 [0.86, 1.27]

0%

148

141

7 [-20, 38]

Moderate §

A composite of death and neurodevelopmental
impairment

3041 (3)

1.01 [0.93, 1.09]

7%

473

468

5 [-33, 42]

High

Bronchopulmonary dysplasia

3034 (5)

0.96 [0.90, 1.03]

0%

462

481

-19 [-48,
14]

Moderate §

Necrotizing enterocolitis

3346 (5)

0.99 [0.84, 1.16]

0%

140

141

-1 [-23, 23]

Moderate §

Retinopathy�3

3054 (5)

0.88 [0.75, 1.03]

0%

156

177

-21 [-44, 5]

Moderate §

Bowel perforation

1461 (2)

1.28 [0.75, 2.18]

45% 62

81

-17 [-16,
74]

Low §¶

Sepsis

1494 (3)

1.06 [0.88, 1.26]

0%

226

213

13 [-26, 55]

Moderate §

Length of hospital stay

3453 (6)

0.65 [-1.91,
3.21]

0%

——

——

——

Moderate §

Intraventricular hemorrhage grade 3 or 4

1146 (3)

0.79 [0.53, 1.17]

0%

70

89

-19 [-42,
15]

Moderate §

Periventricular leukomalacia

1547 (3)

0.80 [0.33, 1.93]

45% 37

46

-9 [-31, 44]

Low &

¶

serious inconsistency.

§

serious imprecision.

&

very serious imprecision.

https://doi.org/10.1371/journal.pone.0256810.t002

neurodevelopmental impairment within 2 years, and one trial evaluated the outcome at the
18–21 months. Fig 4 shows that no significant difference in the long-term neurodevelopmental
impairment between restrictive and liberal transfusion (RR 1.08, 95% CI [0,88, 1.33]).

Secondary efficacy outcome
Findings are summarized in Table 2 and Fig 5. Three trials with a combined total of 3,041
patients investigated a composite of death or neurodevelopmental impairment. A total of 721
events in restrictive transfusion and 705 events in liberal transfusion were reported. The
pooled analysis showed no significant difference between restrictive and liberal transfusion
thresholds (RR 1.01; 95% CI [0.93, 1.09]).

Safety outcomes
Table 2 summarizes findings of safety outcomes. Restrictive transfusion was not associated
with increased incidences of any adverse events, including bronchopulmonary dysplasia (RR
0.96; 95% CI [0.90, 1.03]), necrotizing enterocolitis (RR 0.99; 95% CI [0.84, 1.16]), retinopathy
of prematurity stage 3 and above (RR 0.88; 95% CI [0.75, 1.03]), intestinal perforation (RR
1.28; 95% CI [0.75, 2.18]), sepsis (RR 1.06; 95% CI [0.88, 1.26]), length of hospital stay (RR
0.65; 95% CI [-1.91, 3.21]), intraventricular hemorrhage grade 3 and above (RR 0.75; 95% CI
[0.53, 1.17]), periventricular leukomalacia (RR 0.80; 95% CI [0.33, 1.93]) and hemoglobin levels(MD -1.37; 95% CI [-2.53,-0.22]) (S5–S13 Figs).

Discussion
To our knowledge, this study is the first comprehensive systematic review with meta-analysis
to evaluate the effect of transfusion thresholds on long-term mortality in VLBW infants. In
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Fig 2. (A) Forest plot comparing overall mortality between restrictive and liberal RBC transfusion thresholds for
VLBW infants. (B) Forest plot comparing long-term mortality between restrictive and liberal RBC transfusion
thresholds. (C) Forest plot comparing short-term mortality between restrictive and liberal RBC transfusion thresholds.
RBC: Red blood cell; VLBW: Very low birth weight.
https://doi.org/10.1371/journal.pone.0256810.g002

Fig 3. Subgroup analysis for all-cause mortality. VLBW: Very low birth weight; ELBW: Extremely low birth weight.
https://doi.org/10.1371/journal.pone.0256810.g003
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Fig 4.
https://doi.org/10.1371/journal.pone.0256810.g004

this meta-analysis of 6 trials with a total of 3,483patients, restrictive transfusion threshold was
not associated with a higher rate of long-term or short-term mortality, long-term neurodevelopmental impairment, as well as the composite outcome. Also, there were no significant differences in other safety outcomes (bronchopulmonary dysplasia, necrotizing enterocolitis,
retinopathy of prematurity stage 3 and above, intestinal perforation, sepsis, LOS, intraventricular hemorrhage grade 3 or 4, and periventricular leukomalacia). Subgroup analysis detected no
significant findings.

Comparison with other studies
To date, only two meta-analysis focused on the effects of restrictive versus liberal RBC transfusion thresholds on clinical outcomes in very low birth weight infants has been published
[38,39]. In 2014, Ibrahim et al. [38] analyzed three trials with a total of 625 infants, concluding
that restrictive RBC transfusion thresholds in VLBW infants may be utilized without incurring
clinically important increases in the risk of death or major short-term neonatal morbidities.
However, outcomes at extended follow-up for one of the largest studies was published in a separate paper that was missed in this meta-analysis [13]. In 2012, the other meta-analysis
included 636 infants drew similar conclusions [39]. However, the previous reviews did not
assess the differences of restrictive versus liberal transfusion thresholds on long-term mortality, long-term neurodevelopmental impairment, and the composite of death or neurodevelopmental impairment. Previous reviews are limited by small sample size. Recently, a metaanalysis included 18 studies revealed that RBC transfusion was associated with ROP (OR 1.50;
95% CI [1.27, 1.76]) [40]. And the use of supplemental oxygen is a risk factor to cause of ROP,
but in the present meta-analysis we found that there was no difference between restrictive and
liberal transfusion thresholds in retinopathy of prematurity stage 3 and above (RR 0.88; 95%
CI [0.75, 1.03]). we also found that restrictive was associated with a more decrease in the
hemoglobin level (MD -1.37; 95% CI [-2.53, -0.22]). Previous studies have also shown that iron
deficiency [22,23] is an important risk factor for neurodevelopment, but the present study did

Fig 5. Forest plot comparing the composite death and neurodevelopmental impairment between restrictive and liberal RBC transfusion for
VLBW infants. RBC: Red blood cell; VLBW: Very low birth weight.
https://doi.org/10.1371/journal.pone.0256810.g005
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not find any difference regarding the long-term neurodevelopmental impairment (RR 1.08,
95% CI [0,88, 1.33]), mortality or other clinical outcomes. These results are consistent with the
fact that erythropoietin failed to improve neurodevelopmental outcomes despite the increase
in the number of red blood cells and hemoglobin concentration [41].
The methodology and data of this study are different from those of previous meta-analysis.
First, we included two recent trials on this topic [35,37] and an undated trial [36], a feature
that accounted for 94.4% of the total number of patients included in this study, which helped
reinforce the findings, decrease the heterogeneity, and improve the precision. Second, we
chose death as the primary outcome of this study instead of adverse outcomes, which was usually selected by previous studies, because death is the most important outcome in VLBW
infants. In addition, several adverse outcomes were reported, which provided a comprehensive
perspective. Third, we identified several new findings, including no difference on the composite of death and neurodevelopmental impairment. Fourth, we identified several new subgroup
analyses based on patients’ characteristics (whether including only ELBW infants, gestational
age, male infants, transfusion volume). After careful examination of this meta-analysis using
the GRADE approach and TSA method, the quality of evidence of the primary outcome was
rated as high.

Strengths and limitations
The major strength in our review is the strict methodology implemented, which followed
the recommendations of the Cochrane Collaboration and PRISMA statement, including a
protocol, an up-to-date literature search and study selection, data extraction, and risk of
bias assessment by two independent investigators. We followed the GRADE approach to
assess the degree of certainty in pooled estimates of effect and presented absolute and relative risks. Trial sequential analysis was also used for the primary outcome to explore
whether cumulative data were adequately powered to evaluate outcome. This meta-analysis
was larger than previous studies aimed at the same subject, and was robust despite sensitivity analyses.
Several limitations must be considered. First, there were differences across trials in inclusion criteria in terms of birth weight. However, after excluding specified trials, the results
remained robust (see in S3 Table). Second, TOP trial was the largest trial we included and contributed the most to the results; nevertheless, the primary outcome remained the same after
excluding it. Third, trials had different definitions of restrictive or liberal thresholds, which
makes it hard to compare different trials directly head-to-head. A related problem was that
there is a significant percentage of patients where the RBC transfusion was not given to protocol, or was given due to an exceptional indication such as major surgery or other emergency
but not due to a hematocrit going below a threshold. The percentages between the two arms
could be large enough to influence results. Since such details are only reported in the larger trials, we did not investigate this discrepancy quantitatively. Standardization of the hemoglobin
or hematocrits transfusion thresholds of RBC is necessary in clinic practice. Definitions of
restrictive and liberal transfusion threshold of each trial were shown in S2 Table. Fourth, we
did not detect a small-study effect bias because we only included six trials. However, any
potential publication bias is likely insignificant since all trials taken separately did not report
any significant findings regarding mortality.

Implications
The 2015 guidelines for transfusion therapy in neonatology declared that “the transfusion criteria used for VLBW babies are based more on consensus of opinions of “experts” than on
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scientific evidence” [24]. There was insufficient evidence to evaluate whether a restrictive
transfusion strategy is effective in limiting transfusions without increasing morbidity and mortality in VLBW infants. Despite this, several guidelines used different thresholds to differentiate restrictive and liberal transfusion. These thresholds varied within individual countries and
within individual Neonatal Units (NNUs) [5,42].
This meta-analysis suggests that in very low birth weight infants who need to receive RBC
transfusions, the use of restrictive transfusion does not increase all-cause mortality,long-term
neurodevelopment impairment, and the composite death and neurodevelopment impairment
outcome. However, there are several differences in transfusion-related variables, including the
definition of thresholds for RBC transfusion, duration of blood transfusion, and the transfusion volume. Future research is required to focus on these issues, especially to precisely define
the optimal thresholds that maximize benefits and minimize harms. This new evidence should
lead us to reconsider the prior recommendations.
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